Project Grant K01HL186166
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of Colorado (University of Colorado-Denver) $163,285 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support a five-year career development project studying the intersection of cardiovascular disease and cancer. The award funds research investigating how colon cancer mediates arterial remodeling through smooth muscle cell phenotypic changes via PDGFR-B signaling. The project...
- The National Heart, Lung, and Blood Institute awarded $338,934 to The Regents of the University of Colorado, doing business as University of Colorado-Denver, on September 18, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) for a K01 mentored career development award titled "Start Strong: A Mixed Methods Study to Inform Initial Antihypertensive Prescribing and a Patient-Self Titration Intervention to Improve Blood Pressure Control, Safety, and Reduce Cardiovascular...
- The National Institute of Child Health and Human Development awarded The Regents Of The University Of Colorado (doing business as University Of Colorado-Denver) $636,728 for a Project Grant in Child Health and Human Development Extramural Research (CFDA 93.865) effective August 4, 2026. The award funds a multicenter prospective study measuring physical activity recovery in children who survive acute respiratory disease requiring invasive mechanical ventilation in pediatric intensive care...
- The National Heart, Lung, and Blood Institute awarded The Regents Of The University Of Colorado (University of Colorado-Denver) $169,225 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support a K23 career development grant. The award funds Dr. Rochelle Cason-Wilkerson's research into targeted intervention and process strategies (TIPS) to enhance health outcomes and reduce attrition in preschool-aged children with obesity. The research adapts an existing...
- The National Heart, Lung, and Blood Institute awarded Duke University $136,646 under the Cardiovascular Diseases Research program (CFDA 93.837) on September 19, 2025, to conduct a K01 Career Development Award examining sex differences in barriers and predictors of physical activity participation during and following cardiac rehabilitation. The award is structured as a Project Grant with performance through August 31, 2030, at Duke University in Durham, North Carolina. The recipient will...
- The National Heart, Lung, and Blood Institute awarded The Regents Of The University Of Colorado (University of Colorado–Denver) $161,583 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to support Dr. Curtis Tilves's transition to an independent scientist through mentored research training. Tilves, a research associate at the LifeCourse Epidemiology of Adiposity and Diabetes (LEAD) Center at University of Colorado Anschutz Medical Campus, will develop...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of Colorado, doing business as University of Colorado-Denver, $117,000 on July 7, 2026, for a proof-of-concept study examining aerobic exercise as a countermeasure to cardiometabolic impairments caused by circadian misalignment in night shift workers, funded under the Cardiovascular Diseases Research program (CFDA 93.837). The research will employ a randomized crossover study with a six-day simulated shiftwork...
- The National Institutes of Health National Heart Lung and Blood Institute awarded $150,104 to The Regents Of The University Of Colorado (University of Colorado-Denver) on January 26, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) for a Project Grant (F32HL179804) to investigate lysine myristoylation as a regulatory mechanism for protein kinase A (PKA) in cardiac tissue. The award funds research examining how histone deacetylase 11 (HDAC11) inhibition increases PKA...
- The National Cancer Institute awarded The Regents Of The University Of Colorado, doing business as University Of Colorado-Denver, $189,653 on September 1, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop and pilot-test the LISTEN intervention, a clinical and electronic health record integration strategy for symptom screening and management in children undergoing cancer treatment. The award funds Dr. L'Hotta's research to adapt an evidence-based symptom management...
- The National Heart, Lung, and Blood Institute awarded Rowan University $271,250 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a pilot trial testing physical activity partnerships for midlife women with elevated cardiovascular disease risk. The award funds a 12-week physical activity skills coaching program using intensive ambulatory assessment. The trial will enroll 160 insufficiently active women ages 40–65 with one or more CVD risk factors...
The National Heart, Lung, and Blood Institute awarded The Regents of the University of Colorado (University of Colorado-Denver) $168,691 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to refine, augment, and pilot test an affect-based physical activity promotion program for cancer survivors at elevated risk of cardiovascular disease. The award funds a K01 Career Development Award with a five-year period of performance through July 31, 2031. Work is performed in Aurora, Colorado. During the project's first aim, the recipient will employ human-centered design techniques to gather information from stakeholders and end-users to maximize fit between a redesigned intervention and user preferences, and to create three novel affect-based intervention components grounded in Acceptance and Commitment Therapy (ACT) principles to address affective barriers to physical activity. During the second aim, the recipient will evaluate usability, feasibility, and acceptability of the program in a 2³ pilot factorial trial involving 64 adult cancer survivors over a six-month intervention period. All participants will receive a core program comprising ACT training and cancer-specific physical activity education; participants will be randomized to receive up to three additional intervention components developed during the first aim. Two integrated frameworks will guide the approach across both aims.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $168.7k | 7/23/26 |